Targeting Dynamic Pockets of HIV-1 Protease by Structure-Based Computational Screening for Allosteric Inhibitors

We present the discovery of low molecular weight inhibitors of human immunodeficiency virus 1 (HIV-1) protease subtype B that were identified by structure-based virtual screening as ligands of an allosteric surface cavity. For pocket identification and prioritization, we performed a molecular dynamics simulation and observed several flexible, partially transient surface cavities. For one of these presumable ligand-binding pockets that are located in the so-called "hinge region" of the identical protease chains, we computed a receptor-derived pharmacophore model, with which we retrieved fragment-like inhibitors from a screening compound pool. The most potent hit inhibited protease activity in vitro in a noncompetitive mode of action. Although attempts failed to crystallize this ligand bound to the enzyme, the study provides proof-of-concept for identifying innovative tool compounds for chemical biology by addressing flexible protein models with receptor pocket-derived pharmacophore screening.

[1]  R. Nussinov,et al.  Allostery: absence of a change in shape does not imply that allostery is not at play. , 2008, Journal of molecular biology.

[2]  Peter G Wolynes,et al.  The folding and dimerization of HIV-1 protease: evidence for a stable monomer from simulations. , 2004, Journal of molecular biology.

[3]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[4]  G Tiana,et al.  HIV-1 protease folding and the design of drugs which do not create resistance. , 2008, Current opinion in structural biology.

[5]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[6]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[7]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[8]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[9]  Petra Schneider,et al.  Scaffold Hopping by “Fuzzy” Pharmacophores and its Application to RNA Targets , 2007, Chembiochem : a European journal of chemical biology.

[10]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[11]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[12]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[13]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[14]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[15]  Irene T Weber,et al.  HIV-1 protease: structure, dynamics, and inhibition. , 2007, Advances in pharmacology.

[16]  T. Yonetani The Yonetani-Theorell graphical method for examining overlapping subsites of enzyme active centers. , 1982, Methods in enzymology.

[17]  R. Yusof,et al.  Rational Discovery of Dengue Type 2 Non‐Competitive Inhibitors , 2013, Chemical biology & drug design.

[18]  Johann Gasteiger,et al.  Impact of Conformational Flexibility on Three-Dimensional Similarity Searching Using Correlation Vectors , 2006, J. Chem. Inf. Model..

[19]  A. Christopoulos Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[20]  Hong Cao,et al.  Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. , 2013, Chemistry & biology.

[21]  D. Scott,et al.  Fragment-based approaches in drug discovery and chemical biology. , 2012, Biochemistry.

[22]  Petra Schneider,et al.  Inhibitors of Helicobacter pylori Protease HtrA Found by ‘Virtual Ligand’ Screening Combat Bacterial Invasion of Epithelia , 2011, PloS one.

[23]  Sukwon Hong,et al.  Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. , 2010, The Biochemical journal.

[24]  J. Thornton,et al.  The structural basis of allosteric regulation in proteins , 2009, FEBS letters.

[25]  P. P. Ewald Die Berechnung optischer und elektrostatischer Gitterpotentiale , 1921 .

[26]  X. Qiu,et al.  Recent developments of peptidomimetic HIV-1 protease inhibitors. , 2011, Current medicinal chemistry.

[27]  G. Schneider,et al.  PocketPicker: analysis of ligand binding-sites with shape descriptors , 2007, Chemistry Central Journal.

[28]  R. Nussinov,et al.  Is allostery an intrinsic property of all dynamic proteins? , 2004, Proteins.

[29]  J. E. Elder,et al.  Fragment‐Based Screen against HIV Protease , 2010, Chemical biology & drug design.

[30]  T. Yonetani,et al.  STUDIES ON LIVER ALCOHOL HYDROGENASE COMPLEXES. 3. MULTIPLE INHIBITION KINETICS IN THE PRESENCE OF TWO COMPETITIVE INHIBITORS. , 1964, Archives of biochemistry and biophysics.

[31]  Structure of the unbound form of HIV-1 subtype A protease: comparison with unbound forms of proteases from other HIV subtypes. , 2010, Acta crystallographica. Section D, Biological crystallography.

[32]  V. Hornak,et al.  Targeting structural flexibility in HIV-1 protease inhibitor binding. , 2007, Drug discovery today.

[33]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[34]  J. Konvalinka,et al.  Current and Novel Inhibitors of HIV Protease , 2009, Viruses.

[35]  Alexander Klenner,et al.  'Fuzziness' in pharmacophore-based virtual screening and de novo design. , 2010, Drug discovery today. Technologies.

[36]  Narayanan Eswar,et al.  Protein structure modeling with MODELLER. , 2008, Methods in molecular biology.

[37]  J. Wells,et al.  Discovery of an allosteric site in the caspases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Rollinger,et al.  Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. , 2010, Journal of medicinal chemistry.